Eli Lilly is a safer way to capitalize on AI-driven drug discovery.

RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...

Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology. The company has a broad pipeline across various therapeutic areas and ...

Announcing an artificial intelligence (AI) drug discovery partnership with Nvidia earlier this month, Recursion co-founder and CEO Chris Gibson, PhD, spoke as much about dollars as he did about drugs ...

Unmet clinical needs often serve as the fundamental driving force behind drug discovery programs. During lead discovery, an intensive search ensues to find a drug-like small molecule or biological ...

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024. SALT LAKE CITY, May ...

This thesis makes the case for an investment in Recursion Pharmaceuticals operating as a TechBio which "industrializes" the process of drug discovery in contrast to a typical biotech. The difference ...

Recursion is forging key relationships with powerful collaborators. The young biotech's valuation is also looking a lot better now. However, its finances are nowhere near breakeven yet. In particular, ...

Recursion is hosting about 60 investors and analysts at its headquarters in Utah. It has generated tons of data with AI and robots, aiming to find a better way to make drugs. Recursion, which has four ...

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...